This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
United Therapeutics (UTHR) Gains on Tyvaso DPI Approval
by Zacks Equity Research
The FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH patients. It is a dry-powder inhalation formulation of Treprostinil. Stock gains 8.8%.
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
United Therapeutics (UTHR) Q1 Earnings & Sales Beat, Stock Up
by Zacks Equity Research
United Therapeutics' (UTHR) first-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.
United Therapeutics (UTHR) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 69.93% and 12.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UnitedHealth (UNH) to Post Q1 Earnings: What to Expect
by Zacks Equity Research
UnitedHealth Group's (UNH) first-quarter results are likely to reflect the benefits of improving premiums and products.
United Therapeutics (UTHR) Moves 3.1% Higher: Will This Strength Last?
by Zacks Equity Research
United Therapeutics (UTHR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Pacira's (PCRX) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) earnings surpass estimates in the fourth quarter of 2021 while revenues are slightly above estimates.
United Therapeutics (UTHR) Q4 Earnings & Sales Miss, Stock Down
by Zacks Equity Research
United Therapeutics (UTHR) fourth-quarter earnings and sales miss estimates. Higher sales of Tyvaso and Unituxin mainly drive the top line in the quarter, offset by lower sales of other drugs.
Down 14.1% in 4 Weeks, Here's Why You Should You Buy the Dip in United Therapeutics (UTHR)
by Zacks Equity Research
The heavy selling pressure might have exhausted for United Therapeutics (UTHR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
United Therapeutics (UTHR) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of -37.67% and 1.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Is United Therapeutics (UTHR) Stock a Suitable Value Pick Now?
by Zacks Equity Research
Let's see if United Therapeutics Corporation (UTHR) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
ImmunoGen (IMGN) Up on Licensing Deal With Lilly Worth $1.7 B
by Zacks Equity Research
ImmunoGen (IMGN) inks a licensing agreement with Eli Lilly, granting the latter rights to develop and commercialize ADCs directed toward targets selected by Lilly. Stock up.
Corcept's (CORT) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Corcept's (CORT) earnings beat estimates in the fourth quarter of 2021 while revenues miss the same.
United Therapeutics (UTHR) Down 6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
United Therapeutics (UTHR) Q3 Earnings & Sales Beat, Stock Up
by Zacks Equity Research
United Therapeutics (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.
United Therapeutics (UTHR) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 1.48% and 6.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA (Revised)
by Zacks Equity Research
United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.
United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA
by Zacks Equity Research
United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.
United Therapeutics (UTHR) Up 3.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Stock Up
by Zacks Equity Research
United Therapeutics (UTHR) second-quarter earnings and sales beat estimates. Higher sales of Orenitram, Unituxin and Tyvaso mainly drive the top line in the quarter.
United Therapeutics (UTHR) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 27.62% and 17.66%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) to Report Q2 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3D Systems (DDD) Joins CollPlant for Bioprinted Breast Tissue Matrix
by Zacks Equity Research
The collaborative efforts of 3D Systems (DDD) and CollPlant aim to eliminate the odds of adverse immune response in the human body induced by procedures using tissue derived from humans and animals.